Inventiva Yönetim

Yönetim kriter kontrolleri 2/4

Inventiva CEO'su Frederic Cren, Jan2011 tarihinde atandı, in görev süresi 13.83 yıldır. in toplam yıllık tazminatı € 1.00M olup, şirket hissesi ve opsiyonları dahil olmak üzere 30.4% maaş ve 69.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 6.45% ine doğrudan sahiptir ve bu hisseler € 13.95M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 8.2 yıl ve 7.8 yıldır.

Anahtar bilgiler

Frederic Cren

İcra Kurulu Başkanı

€1.0m

Toplam tazminat

CEO maaş yüzdesi	30.4%
CEO görev süresi	13.8yrs
CEO sahipliği	6.4%
Yönetim ortalama görev süresi	8.2yrs
Yönetim Kurulu ortalama görev süresi	7.8yrs

Son yönetim güncellemeleri

Shareholders May Not Be So Generous With Inventiva S.A.'s (EPA:IVA) CEO Compensation And Here's Why

Jun 14

Recent updates

Inventiva S.A. (EPA:IVA) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

Sep 27

More Unpleasant Surprises Could Be In Store For Inventiva S.A.'s (EPA:IVA) Shares After Tumbling 28%

Jun 18

Shareholders May Not Be So Generous With Inventiva S.A.'s (EPA:IVA) CEO Compensation And Here's Why

Jun 14

Optimistic Investors Push Inventiva S.A. (EPA:IVA) Shares Up 27% But Growth Is Lacking

Mar 19

CEO Tazminat Analizi

Frederic Cren'un ücretlendirmesi Inventiva'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-€104m
Mar 31 2024	n/a	n/a	-€107m
Dec 31 2023	€1m	€305k	-€110m
Sep 30 2023	n/a	n/a	-€95m
Jun 30 2023	n/a	n/a	-€80m
Mar 31 2023	n/a	n/a	-€67m
Dec 31 2022	€878k	€300k	-€54m
Sep 30 2022	n/a	n/a	-€55m
Jun 30 2022	n/a	n/a	-€56m
Mar 31 2022	n/a	n/a	-€56m
Dec 31 2021	€929k	€299k	-€50m
Sep 30 2021	n/a	n/a	-€45m
Jun 30 2021	n/a	n/a	-€41m
Mar 31 2021	n/a	n/a	-€36m
Dec 31 2020	€388k	€267k	-€34m
Sep 30 2020	n/a	n/a	-€29m
Jun 30 2020	n/a	n/a	-€25m
Mar 31 2020	n/a	n/a	-€27m
Dec 31 2019	€374k	€243k	-€30m
Sep 30 2019	n/a	n/a	-€34m
Jun 30 2019	n/a	n/a	-€37m
Mar 31 2019	n/a	n/a	-€35m
Dec 31 2018	€376k	€243k	-€33m
Sep 30 2018	n/a	n/a	-€29m
Jun 30 2018	n/a	n/a	-€25m
Mar 31 2018	n/a	n/a	-€22m
Dec 31 2017	€372k	€243k	-€19m

Tazminat ve Piyasa: Frederic 'nin toplam tazminatı ($USD 1.09M ), French pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 462.45K ).

Tazminat ve Kazançlar: Frederic şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Frederic Cren (58 yo)

13.8yrs

Görev süresi

€1,003,699

Tazminat

Mr. Frederic Cren has been Chief Executive Officer of Inventiva S.A. since co-founding Inventiva S.A. in 2011. Mr. Cren has been Chairman at Inventiva S.A. since May 31, 2016. He served as President of Inv...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Frederic Cren	Co-Founder	13.8yrs	€1.00m	6.45% € 13.9m
Pierre Broqua	Co-Founder	13.8yrs	€938.43k	4.46% € 9.6m
Jean Volatier	Deputy GM & CFO	12.3yrs	Veri yok	0.17% € 372.3k
Alice Roudot-Ketelers	Chief Operating Officer	1.8yrs	Veri yok	0.017% € 37.3k
Eric Duranson	General Counsel	3.3yrs	Veri yok	0.017% € 37.3k
Nathalie Harroy	Head of Human Resources	12.8yrs	Veri yok	0.075% € 163.3k
Kristina Meyer	Executive VP and Business Development & Alliance Management	no data	Veri yok	Veri yok
Michael Cooreman	Chief Medical Officer	4.1yrs	Veri yok	0.017% € 37.3k
Pascaline Clerc	Executive Vice President of Strategy & Corporate Affairs	1.1yrs	Veri yok	0.0086% € 18.6k

8.2yrs

Ortalama Görev Süresi

57.5yo

Ortalama Yaş

Deneyimli Yönetim: IVA 'un yönetim ekibi deneyimli ve deneyimlidir ( 8.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Frederic Cren	Co-Founder	8.5yrs	€1.00m	6.45% € 13.9m
Pierre Broqua	Co-Founder	8.5yrs	€938.43k	4.46% € 9.6m
Chris Buyse	Independent Director	7.8yrs	€61.20k	0% € 0
Annick Schwebig	Independent Director	7.8yrs	€61.20k	0.0035% € 7.6k
Jean-Louis Junien	Chairman of Scientific Advisory Board	no data	€16.00k	Veri yok
Xiaoqin Lu	Independent Director	6.5yrs	€43.20k	Veri yok
Heinz Maeusli	Independent Director	5.5yrs	€49.20k	Veri yok
Sven Francque	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Manal Abdelmalek	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Kenneth Cusi	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Glen Clack	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Gérard Zalcman	Scientific Advisory Board Member	no data	Veri yok	Veri yok

7.8yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: IVA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.8 yıldır).

Inventiva Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Shareholders May Not Be So Generous With Inventiva S.A.'s (EPA:IVA) CEO Compensation And Here's Why

Inventiva S.A., Annual General Meeting, Jan 25, 2023

Inventiva Announces Lucy Lu as the Director of its Board of Directors

Insufficient new directors

Insufficient new directors

Inventiva S.A., Annual General Meeting, May 19, 2022

Recent updates

Inventiva Announces the Positive Recommendation of the Fifth DMC of the Nativ3 Phase 3 Clinical Trial with Lanifibranor in Patients with Mash

New major risk - Shareholder dilution

Consensus revenue estimates increase by 81%, EPS downgraded

Inventiva S.A. announced that it expects to receive €348 million in funding from a group of investors

Price target decreased by 9.0% to €9.68

Consensus EPS estimates upgraded to €1.21 loss, revenue downgraded

Inventiva S.A. (EPA:IVA) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

First half 2024 earnings released: €0.94 loss per share (vs €1.32 loss in 1H 2023)

Price target decreased by 20% to €10.64

Consensus revenue estimates increase by 113%

More Unpleasant Surprises Could Be In Store For Inventiva S.A.'s (EPA:IVA) Shares After Tumbling 28%

Shareholders May Not Be So Generous With Inventiva S.A.'s (EPA:IVA) CEO Compensation And Here's Why

Consensus revenue estimates decrease by 67%

Inventiva Announces the Publication in Nature Communications of Additional Results from Native Phase IIb Clinical Trial Demonstrating Improvement of Markers of Cardiometabolic Health in Patients with MASH/NASH Treated with Lanifibranor

Consensus revenue estimates decrease by 21%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Optimistic Investors Push Inventiva S.A. (EPA:IVA) Shares Up 27% But Growth Is Lacking

New minor risk - Share price stability

Inventiva S.A. Provides Update on its Clinical Trial NATiV3

Some Confidence Is Lacking In Inventiva S.A.'s (EPA:IVA) P/S

Consensus EPS estimates fall by 13%

Forecast to breakeven in 2026

Inventiva S.A. to Report First Half, 2024 Results on Sep 25, 2024

Price target decreased by 14% to €15.35

Inventiva Announces the Randomization of the First Patient in China in the NATiV3 Clinical Trial and Provides an Update on Its Clinical Development Program

Price target decreased by 7.4% to €16.50

New major risk - Negative shareholders equity

First half 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 216%

New major risk - Negative shareholders equity

Consensus revenue estimates decrease by 78%

New major risk - Financial position

New minor risk - Shareholder dilution

Consensus revenue estimates decrease by 19%

Inventiva S.A. to Report Fiscal Year 2023 Results on Mar 27, 2024

Consensus revenue estimates increase by 573%

Inventiva S.A. to Report Nine Months, 2023 Results on Sep 28, 2023

New major risk - Revenue and earnings growth

Price target increased by 15% to €18.76

Inventiva Announces Positive Topline Results from the Investigator-Initiated Phase Ii Clinical Trial Evaluating Lanifibranor in Patients with T2d and NAFLD

Analyst Forecasts Just Became More Bearish On Inventiva S.A. (EPA:IVA)

Consensus revenue estimates decrease by 15%

Pinning Down Inventiva S.A.'s (EPA:IVA) P/S Is Difficult Right Now

Consensus revenue estimates decrease by 37%

Revenue Downgrade: Here's What Analysts Forecast For Inventiva S.A. (EPA:IVA)

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2025

Inventiva S.A. to Report Fiscal Year 2022 Results on Mar 29, 2023

Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated Cirrhosis

Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated Cirrhosis

Inventiva S.A., Annual General Meeting, Jan 25, 2023

Inventiva Announces Lucy Lu as the Director of its Board of Directors

Insufficient new directors

Inventiva Provides Update on Development of cedirogant by AbbVie

Consensus revenue estimates increase by 10%

Consensus revenue estimates increase by 352%

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Inventiva S.A. to Report First Half, 2022 Results on Sep 21, 2022

Inventiva Announces the Screening of the First Patient in LEGEND , Phase IIa Combination Trial with Lanifibranor and Empagliflozin in Patients with NASH and T2D

Despite Lacking Profits Inventiva (EPA:IVA) Seems To Be On Top Of Its Debt

Price target decreased to €19.96

Inventiva Announces Three Scientific Presentations At the EASL International Liver Congress™ 2022

Insufficient new directors

Consensus forecasts updated

No longer forecast to breakeven

Inventiva S.A., Annual General Meeting, May 19, 2022

Inventiva S.A. Announces IND Application for the Phase Ii Combination Trial with Lanifibranor and Empagliflozin in Patients with Nash

Forecast to breakeven in 2024

Inventiva S.A. to Report Fiscal Year 2021 Results on Mar 07, 2022